The bidding war goes on to acquire Obagi Medical Products (NASDAQ: OMPI) and its dermatological product line, with the acquisitive Valeant Pharmaceuticals (BHC -2.67%) as the current top bidder at $24 per share. The ongoing bidding war has Obagi up another 10% today. Are we close to seeing a deal? In this video, Fool health-care analyst David Williamson tells investors how to play this buyout bidding race, both for current shareholders, and for those currently sitting on the sidelines.
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Is this pharmaceutical finally close to being acquired?
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.